You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Citation Tools

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Song Y, Li N, Li Q, et al
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Journal for ImmunoTherapy of Cancer 2020;8:e001279. doi: 10.1136/jitc-2020-001279